This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Knox, R. J. Articles by Burke, P. J. Search for Related Content PubMed PubMed Citation Articles by Knox, R. J. Articles by Burke, P. J.

Bioactivation of 5-(Aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) by Human NAD(P)H Quinone Oxidoreductase 2: A Novel Co-substrate-mediated Antitumor Prodrug Therapy¹

Enact Pharma Plc, Porton Down Science Park, Salisbury SP4 0JQ, United Kingdom [R. J. K., R. G. M., P. J. B.]; Yorkshire Cancer Research Laboratory of Drug Design, Cancer Research Unit, University of Bradford, Bradford BD7 1DP, United Kingdom [T. C. J.]; CRC Centre for Cancer Therapeutics, Institute of Cancer Research, Sutton, Surrey SM2 5NG, United Kingdom [S. M. H.]; and Division of Immunology, Beckman Research Institute of the City of Hope, Duarte, California 91010-0269 [S. C.]

A novel prodrug activation system, endogenous in human tumor cells, is described. A latent enzyme-prodrug system is switched on by a simple synthetic, small molecule co-substrate. This ternary system is inactive if any one of the components is absent. CB 1954 [5-(aziridin-1-yl)-2,4-dinitrobenzamide] is an antitumor prodrug that is activated in certain rat tumors via its 4-hydroxylamine derivative to a potent bifunctional alkylating agent. However, human tumor cells are resistant to CB 1954 because they are unable to catalyze this bioactivation efficiently. A human enzyme has been discovered that can activate CB 1954, and it has been shown to be commonly present in human tumor cells. The enzyme is NQO2 [NAD(P)H quinone oxidoreductase 2], but its activity is normally latent, and a nonbiogenic co-substrate such as NRH [nicotinamide riboside (reduced)] is required for enzymatic activity. There is a very large (100–3000-fold) increase in CB 1954 cytotoxicity toward either NQO2-transfected rodent or nontransfected human tumor cell lines in the presence of NRH.

Other reduced pyridinium compounds can also act as co-substrates for NQO2. Thus, the simplest quaternary salt of nicotinamide, 1-methyl-3-carboxamidopyridinium iodide, was a co-substrate for NQO2 when reduced to the corresponding 1,4-dihydropyridine derivative. Increased chain length and/or alkyl load at the 1-position of the dihydropyridine ring improved specific activity, and compounds more active than NRH were found. However, little activity was seen with either the 1-benzyl or 1-(2-phenylethyl) derivatives. A negatively charged substituent at the 3-position of the reduced pyridine ring also negated the ability of these compounds to act as co-substrates for NQO2. In particular, 1-carbamoylmethyl-3-carbamoyl-1,4-dihydropyridine was shown to be a co-substrate for NQO2 with greater stability than NRH, with the ability to enter cells and potentiate the cytotoxicity of CB 1954. Furthermore, this agent is synthetically accessible and suitable for further pharmaceutical development.

NQO2 activity appears to be related to expression of NQO1 (DT-diaphorase), an enzyme that is known to have a favorable distribution toward certain human cancers. NQO2 is a novel target for prodrug therapy and has a unique activation mechanism that relies on a synthetic co-substrate to activate an apparently latent enzyme. Our findings may reopen the use of CB 1954 for the direct therapy of human malignant disease.

This article has been cited by other articles:

				K. Iskander, R. J. Barrios, and A. K. Jaiswal NRH:Quinone Oxidoreductase 2-Deficient Mice Are Highly Susceptible to Radiation-Induced B-Cell Lymphomas Clin. Cancer Res., March 1, 2009; 15(5): 1534 - 1542. [Abstract] [Full Text] [PDF]

				C. Yan, J. K. Kepa, D. Siegel, I. J. Stratford, and D. Ross Dissecting the Role of Multiple Reductases in Bioactivation and Cytotoxicity of the Antitumor Agent 2,5-Diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone (RH1) Mol. Pharmacol., December 1, 2008; 74(6): 1657 - 1665. [Abstract] [Full Text] [PDF]

				Y. Fu, L. Buryanovskyy, and Z. Zhang Quinone Reductase 2 Is a Catechol Quinone Reductase J. Biol. Chem., August 29, 2008; 283(35): 23829 - 23835. [Abstract] [Full Text] [PDF]

				K. S. Ahn, X. Gong, G. Sethi, M. M. Chaturvedi, A. K. Jaiswal, and B. B. Aggarwal Deficiency of NRH:Quinone Oxidoreductase 2 Differentially Regulates TNF Signaling in Keratinocytes: Up-regulation of Apoptosis Correlates with Down-regulation of Cell Survival Kinases Cancer Res., October 15, 2007; 67(20): 10004 - 10011. [Abstract] [Full Text] [PDF]

				A. K. Adikesavan, R. Barrios, and A. K. Jaiswal In vivo Role of NAD(P)H:Quinone Oxidoreductase 1 in Metabolic Activation of Mitomycin C and Bone Marrow Cytotoxicity Cancer Res., September 1, 2007; 67(17): 7966 - 7971. [Abstract] [Full Text] [PDF]

				D. Jamieson, K. Wilson, S. Pridgeon, J. P. Margetts, R. J. Edmondson, H. Y. Leung, R. Knox, and A. V. Boddy NAD(P)H:Quinone Oxidoreductase 1 and NRH:Quinone Oxidoreductase 2 Activity and Expression in Bladder and Ovarian Cancer and Lower NRH:Quinone Oxidoreductase 2 Activity Associated with an NQO2 Exon 3 Single-Nucleotide Polymorphism Clin. Cancer Res., March 1, 2007; 13(5): 1584 - 1590. [Abstract] [Full Text] [PDF]

				K. Iskander, M. Paquet, C. Brayton, and A. K. Jaiswal Deficiency of NRH:Quinone Oxidoreductase 2 Increases Susceptibility to 7,12-Dimethylbenz(a)anthracene and Benzo(a)pyrene-Induced Skin Carcinogenesis Cancer Res., September 1, 2004; 64(17): 5925 - 5928. [Abstract] [Full Text] [PDF]

				M. Rooseboom, J. N. M. Commandeur, and N. P. E. Vermeulen Enzyme-Catalyzed Activation of Anticancer Prodrugs Pharmacol. Rev., March 1, 2004; 56(1): 53 - 102. [Abstract] [Full Text] [PDF]

				D. J. Long II, K. Iskander, A. Gaikwad, M. Arin, D. R. Roop, R. Knox, R. Barrios, and A. K. Jaiswal Disruption of Dihydronicotinamide Riboside:Quinone Oxidoreductase 2 (NQO2) Leads to Myeloid Hyperplasia of Bone Marrow and Decreased Sensitivity to Menadione Toxicity J. Biol. Chem., November 22, 2002; 277(48): 46131 - 46139. [Abstract] [Full Text] [PDF]